Correction to Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2023-10-04 DOI:10.1002/hon.3226

引用次数: 0

Abstract

Suzuki T, Maruyama D, Machida R, et al. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105. Hematol Oncol. 2023;41(3):590–593. https://doi.org/10.1002/hon.3103.

Subsequent to the publication of above article, the authors noted that the serum β2MG data (median level and unit) in Table 1 were incorrect. The correct median β2MG level is 3.1 (range, 1.4–14.3). The correct unit for β2MG is mg/L. This correction does not change the interpretation of the data or the overall conclusions of the study. The corrected Table 1 is shown below. The authors wish to apologize for any inconvenience caused.

查看原文本刊更多论文

英国骨髓瘤研究联盟风险简介对接受美法仑、泼尼松和硼替佐米方案的不符合移植条件的多发性骨髓瘤患者预后影响的校正：JCOG1105的补充分析。

Suzuki T、Maruyama D、Machida R 等. 英国骨髓瘤研究联盟风险简介对接受美法仑、泼尼松龙和硼替佐米方案治疗的不符合移植条件的多发性骨髓瘤患者的预后影响：JCOG1105 补充分析。Hematol Oncol.2023;41(3):590-593. https://doi.org/10.1002/hon.3103.Subsequent 在上述文章发表前，作者指出表1中的血清β2MG数据（中位数水平和单位）有误。正确的 β2MG 水平中位数为 3.1（范围为 1.4-14.3）。β2MG的正确单位是毫克/升。这一更正不会改变数据的解释或研究的总体结论。更正后的表 1 如下。作者对由此造成的不便深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.